Tela Bio, Inc. · NASDAQ:TELA
Tela Bio — Investor Presentation (August 2022)
17 slides from Tela Bio's investor presentation, Aug 15, 2022
Slide 1: Investor Presentation August 2022
INVESTOR PRESENTATION August 2022
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possi
Slide 3: TELA Bio, Inc.
TELA Bio, Inc. • ~$2.2B US market opportunity 1 • Multiple innovative products offering attractive value propositions for hospitals • Growing portfolio of offerings • Compelling, expanding set of clinical data • Increasing GPO/market access 1 Management estimate. $2.2B total includes $1.5B hernia &
Slide 4: Reinforced Tissue Matrix
REINFORCED TISSUE MATRIX @TELABIO SCIENCE. VALUE. INNOVATION.
Slide 5: OviTex: ~$1.5 Billion Annual U.S. Hernia Market Opportunity
Complex, Moderate Ventral / Abdominal Wall Reconstruction Simple Ventral Hernia Repair Inguinal Hernia Repair Hiatal Hernia Repair ~60,000 ~345,000 ~665,000 ~40,000 $360M $515M $600M $40M 1 Sources: Millennium Research Group Reports, IMS Health Data; iData Research MedSKU 2 Management estimate. Mark
Slide 6: OviTex Portfolio: Designed for a Range of Hernia Patients and Surgical Techniques
OviTex Portfolio: Designed for a Range of Hernia Patients and Surgical Techniques • Coated resorbable synthetic meshes • Biologic meshes • Biologic meshes CONFIGURATION OviTex 2S 8 - layer device, with 2 “smooth sides” suitable for intraperitoneal placement Robot Compatible 1 : No Strength 2 : +++ V
Slide 7: Hernia mesh market share shift by material type
Permanent Synthetic Biologic Biosynthetic Resorbable Reinforced Tissue Matrix Other factors: • Lack of Sales Force Emphasis • Lack of Innovation Other factors: • Patient Education • Lack of Innovation Pricing Pressure & Clinical Utility in robotic / laparoscopic procedures is driving a significant d
Slide 8: Need for Alternative to Permanent Synthetic Mesh
Lawsuits against permanent synthetic meshes estimated to be assembled across the U.S. 3 of surgeons agree that use of permanent synthetic mesh puts patients at long - term risk of complications 1 1. Hernia and Abdominal Surgeries Survey (Oct 2020). A group of 71 surgeons were surveyed regarding use
Slide 9: Recurrence Rates: Studies Evaluating OviTex in Ventral Hernia Repairs
Parker, 2020 3 Ankey , Szotek et al., 2021 5 DeNoto, 2022 (BRAVO) 6 Sivaraj , Nazerali et al., 2022 7 Total enrolled patients 50 259 92 36 Length of follow - up 12 months 1 – 58 months 24 months 29 months (Median) VHWG / MVHWG 32% grade 2 68% grade 3 - 57% grade 2 21% grade 3 33% grade 1 58% grade 2
Slide 10: Low Recurrence All Applications with OviTex
LOW RECURRENCE ALL APPLICATIONS WITH OVITEX Ankey , Szotek et al. – 2021 5* 54 patients Follow - up 3 - 38 months Ferzoco – 2018 2* 31 patients Average follow up 13 months INGUINAL 0% Ankey , Szotek et al. – 2021 5* 306 patients Follow up 1 - 36 months INGUINAL 1.6% Sawyer – 2018 8* 25 patients Aver
Slide 11: OviTex PRS
OVITEX FE REINFORCED TISSUE MATRIX @TELABIO SCIENCE. VALUE. INNOVATION.
Slide 12: OviTex PRS: ~$700 Million Annual U.S. Plastic and Reconstructive Surgery Market Opportunity
OviTex PRS: ~$700 Million Annual U.S. Plastic and Reconstructive Surgery Market Opportunity Surgeons use products to reinforce soft tissue during various reconstructive surgeries, including: ▫ Head and neck surgery ▫ Chest wall reconstruction ▫ Pelvic reconstruction ▫ Extremities reconstruction ▫ Br
Slide 13: OviTex PRS: Specifically Designed for Plastic and Reconstructive Surgery
OviTex PRS: Specifically Designed for Plastic and Reconstructive Surgery An innovative reinforced tissue matrix designed to facilitate fluid management and control degree and direction of stretch Product Features: ▫ Layers composed of biologic building block retain macromolecules for tissue regenera
Slide 14: TELA Bio is growing each factor that contributes to sales
TELA Bio is growing each factor that contributes to sales, providing for multi - year, long - term growth 2021: 40 - 45 reps 1H22: 57 reps Driving Revenue Growth Rep Productivity Sales Force Size Product Portfolio GPO Access Clinical Data $ales • Playbook90 training and assessment • 3 - 6 mos. to br
Slide 15: Delivering Revenue Growth
Delivering Revenue Growth Q2 2022 Performance ▫ Revenue growth of 38 % over corresponding period of 2021 ▫ Cash and Cash equivalents (as of June 30, 2022): $ 27.7 M ▫ Entered GPO contract with Premier, Inc. ▫ Highlighted additional positive data from the BRAVO and ReBAR studies ▫ Secured an initial
Slide 16: Investment Rationale
Investment Rationale Advanced reinforced tissue matrix portfolio supported by compelling clinical evidence Focused on ~$2.2 billion annual U.S. total addressable markets – still in early stages of growth Driving commercial adoption with targeted direct - sales approach Recent product launches in gro
Slide 17: Clinical References
CLINICAL REFERENCES 1. DeNoto G 3rd. Bridged repair of large ventral hernia defects using an ovine reinforced biologic: A case series. Ann Med Surg ( Lond ). 2022 Mar 2;75:103446. doi : 10.1016/j.amsu.2022.103446. PMID: 35386793; PMCID: PMC8977941. 2. Ferzoco S.J. Early experience outcome of a reinf